Aravive Inc. (NASDAQ:ARAV), a late clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that it received a $6 million development milestone payment from its licensee, 3D Medicines Inc. This milestone is based on the initiation of the global Phase 3 platinum resistant ovarian cancer (PROC) clinical trial in China for the development of Aravive’s batiraxcept.
There’s Substantial Risk Trump Presidency Will Be ‘Immensely Destructive’ For Economy, Says Larry Summers: ‘It’s A Mistake Not To Be Extraordinarily Alarmed’
Larry Summers says a Trump presidency could prove to be "a profound threat to the long-run prosperity" of the U.S.
